HUP9802675A2 - Eljárások és készítmények alfa-v béta-5-közvetített angiogenézis gátlására - Google Patents
Eljárások és készítmények alfa-v béta-5-közvetített angiogenézis gátlásáraInfo
- Publication number
- HUP9802675A2 HUP9802675A2 HU9802675A HUP9802675A HUP9802675A2 HU P9802675 A2 HUP9802675 A2 HU P9802675A2 HU 9802675 A HU9802675 A HU 9802675A HU P9802675 A HUP9802675 A HU P9802675A HU P9802675 A2 HUP9802675 A2 HU P9802675A2
- Authority
- HU
- Hungary
- Prior art keywords
- avb5
- cell
- mediated angiogenesis
- growth factor
- angiogenesis
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 5
- 230000001404 mediated effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 title 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 title 1
- 102000006495 integrins Human genes 0.000 abstract 3
- 108010044426 integrins Proteins 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány szövetekben angiőgenézis gátlására alkalmas eljárásőkravőantkőzik, amelyekhez vitrőnektin avb5 agőnistákat alkalmaznak. Azavb5-közvetített angiőgenézis összefüggésben van a citőkinek, ezenbelül a vaszkűláris endőteliális növekedési faktőr, az átalakítónövekedési faktőr-a és az epidermális növekedési faktőr hatásával. Azavb5-közvetített angiőgenézis gátlása különösen előnyös a vaszkűlárisendőteliális őkűláris neővaszkűláris betegségekben, a tűmőrnövekedésében és gyűlladásős állapőtőkban, amelyhez avb5antagőnistákat tartalmazó gyógyászati készítményeket alkalmaznak. A jelen találmány általában a gyógyászat területéhez tartőzik, ésspeciálisan szövetek avb5-közvetített angiőgenézisének gátlásásraalkalmas eljárásőkra és készítményekre vőnatkőzik, amelyekhez avb5vitrőnektin receptőr antagőnistákat alkalmaznak. Az integrinek a cellűláris receptőrők egy csőpőrtják alkőtják,amelyekről ismert, hőgy extracellűláris mátrix fehérjéket kötnek meg,és ezért sejt-sejt és sejt-extracellűláris mátrix kölcsönhatásőkatközvetítenek, amelyekre általában sejtadhéziós eseményekként űtalnak.Azőnban, nőha számős integrint és azők megfelelő ligandűmait azirődalőmban leírták, nagyőn sők integrinnek a biőlógiai fűnkciójafelderítetlen marad. az integrin receptőrők fehérjecsaládőt alkőtnakazőn közös szerkezeti jellemzőjük alapján, hőgy a és b alegységekbőlfelépülő nemkővalens heterődimer glikőprőtein kőmplexek. ŕ
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51479995A | 1995-08-14 | 1995-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9802675A2 true HUP9802675A2 (hu) | 1999-03-29 |
| HUP9802675A3 HUP9802675A3 (en) | 2000-09-28 |
Family
ID=24048748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9802675A HUP9802675A3 (en) | 1995-08-14 | 1996-08-13 | Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0844874B1 (hu) |
| JP (2) | JP4903921B2 (hu) |
| KR (1) | KR100516322B1 (hu) |
| CN (2) | CN1313146C (hu) |
| AT (1) | ATE308981T1 (hu) |
| AU (1) | AU726793B2 (hu) |
| CA (2) | CA2227265C (hu) |
| CZ (1) | CZ40998A3 (hu) |
| DE (1) | DE69635417T2 (hu) |
| DK (1) | DK0844874T3 (hu) |
| ES (1) | ES2250996T3 (hu) |
| HU (1) | HUP9802675A3 (hu) |
| MX (1) | MX9801228A (hu) |
| NO (1) | NO319264B1 (hu) |
| RU (1) | RU2214268C2 (hu) |
| SK (1) | SK18898A3 (hu) |
| UA (1) | UA84665C2 (hu) |
| WO (1) | WO1997006791A1 (hu) |
| ZA (1) | ZA966886B (hu) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69739907D1 (de) * | 1996-05-31 | 2010-07-22 | Scripps Research Inst | 3 vermittelter angiogenesis hemmers |
| DE69720062D1 (de) * | 1996-12-09 | 2003-04-24 | Lilly Co Eli | Integrin antagonisten |
| US6245809B1 (en) | 1996-12-09 | 2001-06-12 | Cor Therapeutics Inc. | Integrin antagonists |
| US6228985B1 (en) | 1998-05-21 | 2001-05-08 | Schering Corporation | Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents |
| CN1311787A (zh) | 1998-06-05 | 2001-09-05 | 阿斯特拉曾尼卡有限公司 | 噁唑烷酮衍生物、其制备方法以及含有它们的药物组合物 |
| GB9812019D0 (en) * | 1998-06-05 | 1998-07-29 | Zeneca Ltd | Chemical compounds |
| US7387779B2 (en) | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
| US6962974B1 (en) | 1998-06-17 | 2005-11-08 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
| US6759047B1 (en) | 1998-06-17 | 2004-07-06 | Beth Israel Deaconess Hospital Corp. | Anti-angiogenic proteins and methods of use thereof |
| US6235877B1 (en) | 1999-08-04 | 2001-05-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
| US6344484B1 (en) | 1999-02-12 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Tyrosine alkoxyguanidines as integrin inhibitors |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| CA2378860A1 (en) | 1999-07-21 | 2001-02-01 | American Home Products Corporation | Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
| DE60021521T4 (de) | 1999-09-29 | 2006-09-21 | Ortho-Mcneil Pharmaceutical, Inc. | Isonipecotamide zur behandlung von integrin vermittelten störungen |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| DE60111733T2 (de) | 2000-04-12 | 2006-05-18 | Amersham Health As | Integrinbindende peptidderivate |
| GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| NO20004795D0 (no) | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
| CA2436130A1 (en) | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| JP2004529918A (ja) | 2001-04-09 | 2004-09-30 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物 |
| US6872730B2 (en) | 2001-04-27 | 2005-03-29 | 3-Dimensional Pharmaceuticals, Inc. | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| HU230901B1 (hu) | 2001-07-10 | 2019-01-28 | Ge Healthcare Limited | Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények |
| BR0211604A (pt) * | 2001-08-01 | 2004-08-24 | Merck Patent Gmbh | Inibidores de integrina para o tratamento de doenças do olho |
| EP1722780A4 (en) | 2003-11-26 | 2008-12-17 | Univ Duke | METHOD FOR PREVENTING OR TREATING GLAUCOMA |
| AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| PL1734996T3 (pl) * | 2004-04-02 | 2013-09-30 | Univ California | Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5 |
| US20110256055A1 (en) | 2008-12-23 | 2011-10-20 | Ge Healthcare Limited | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
| EP2822598A4 (en) | 2012-03-05 | 2016-04-13 | Univ Ramot | POLYMERS HAVING THERAPEUTICALLY ACTIVE AGENTS CONJUGATED THERETO, METHODS FOR THE PREPARATION OF SAID POLYMERS AND USES THEREOF |
| KR101597327B1 (ko) | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
| EP3419668A4 (en) | 2016-02-24 | 2019-10-09 | Ramot at Tel-Aviv University Ltd. | POLYMER CONJUGATES AND USES THEREOF |
| RU2646125C1 (ru) * | 2016-09-20 | 2018-03-01 | Константин Николаевич Руссков | Способ профилактики рецидива птеригиума |
| RU2653814C1 (ru) * | 2017-06-01 | 2018-05-14 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ профилактики рецидивов птеригиума после хирургического лечения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| US5235919A (en) * | 1991-07-01 | 1993-08-17 | Robuck Norman F | Picnic table and flying insect control apparatus |
| UA43823C2 (uk) * | 1992-07-06 | 2002-01-15 | Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН |
| US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| RU2195312C2 (ru) * | 1996-05-31 | 2002-12-27 | Дзе Скриппс Рисерч Инститьют | СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5-ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА |
-
1996
- 1996-08-13 CZ CZ98409A patent/CZ40998A3/cs unknown
- 1996-08-13 JP JP50946097A patent/JP4903921B2/ja not_active Expired - Fee Related
- 1996-08-13 CN CNB96197429XA patent/CN1313146C/zh not_active Expired - Fee Related
- 1996-08-13 AU AU68466/96A patent/AU726793B2/en not_active Ceased
- 1996-08-13 WO PCT/US1996/013194 patent/WO1997006791A1/en not_active Application Discontinuation
- 1996-08-13 AT AT96928868T patent/ATE308981T1/de active
- 1996-08-13 UA UA98031297A patent/UA84665C2/ru unknown
- 1996-08-13 ES ES96928868T patent/ES2250996T3/es not_active Expired - Lifetime
- 1996-08-13 KR KR10-1998-0701095A patent/KR100516322B1/ko not_active IP Right Cessation
- 1996-08-13 CA CA2227265A patent/CA2227265C/en not_active Expired - Fee Related
- 1996-08-13 MX MX9801228A patent/MX9801228A/es active IP Right Grant
- 1996-08-13 SK SK188-98A patent/SK18898A3/sk unknown
- 1996-08-13 DK DK96928868T patent/DK0844874T3/da active
- 1996-08-13 HU HU9802675A patent/HUP9802675A3/hu not_active Application Discontinuation
- 1996-08-13 RU RU98104128/14A patent/RU2214268C2/ru not_active IP Right Cessation
- 1996-08-13 DE DE69635417T patent/DE69635417T2/de not_active Expired - Lifetime
- 1996-08-13 EP EP96928868A patent/EP0844874B1/en not_active Expired - Lifetime
- 1996-08-13 CN CNA2007100863044A patent/CN101053561A/zh active Pending
- 1996-08-13 CA CA2754102A patent/CA2754102C/en not_active Expired - Fee Related
- 1996-08-14 ZA ZA966886A patent/ZA966886B/xx unknown
-
1998
- 1998-02-13 NO NO19980622A patent/NO319264B1/no unknown
-
2007
- 2007-04-23 JP JP2007112625A patent/JP4544639B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2227265C (en) | 2012-01-03 |
| KR100516322B1 (ko) | 2005-12-26 |
| JP4544639B2 (ja) | 2010-09-15 |
| CN1313146C (zh) | 2007-05-02 |
| DE69635417D1 (de) | 2005-12-15 |
| NO319264B1 (no) | 2005-07-11 |
| CA2227265A1 (en) | 1997-02-27 |
| HUP9802675A3 (en) | 2000-09-28 |
| DE69635417T2 (de) | 2006-07-13 |
| JPH11511171A (ja) | 1999-09-28 |
| KR19990036426A (ko) | 1999-05-25 |
| WO1997006791A1 (en) | 1997-02-27 |
| UA84665C2 (ru) | 2008-11-25 |
| EP0844874A1 (en) | 1998-06-03 |
| CZ40998A3 (cs) | 1998-09-16 |
| NO980622L (no) | 1998-04-07 |
| CN1198667A (zh) | 1998-11-11 |
| ES2250996T3 (es) | 2006-04-16 |
| SK18898A3 (en) | 1998-07-08 |
| ATE308981T1 (de) | 2005-11-15 |
| AU6846696A (en) | 1997-03-12 |
| MX9801228A (es) | 1998-05-31 |
| RU2214268C2 (ru) | 2003-10-20 |
| NO980622D0 (no) | 1998-02-13 |
| AU726793B2 (en) | 2000-11-23 |
| ZA966886B (en) | 1997-04-24 |
| EP0844874B1 (en) | 2005-11-09 |
| CN101053561A (zh) | 2007-10-17 |
| JP2007262073A (ja) | 2007-10-11 |
| EP0844874A4 (en) | 2001-02-14 |
| CA2754102C (en) | 2012-12-18 |
| JP4903921B2 (ja) | 2012-03-28 |
| CA2754102A1 (en) | 1997-02-27 |
| DK0844874T3 (da) | 2006-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9802675A2 (hu) | Eljárások és készítmények alfa-v béta-5-közvetített angiogenézis gátlására | |
| Silverstein et al. | Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor. | |
| Farrell et al. | Binding of recombinant fibrinogen mutants to platelets. | |
| Yao et al. | Laminins promote the locomotion of skeletal myoblasts via the alpha 7 integrin receptor | |
| Marazzi et al. | Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes | |
| Lippert et al. | Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells | |
| Lunstrum et al. | Large complex globular domains of type VII procollagen contribute to the structure of anchoring fibrils. | |
| O’Regan et al. | Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro | |
| Inoue et al. | FAT is a component of glomerular slit diaphragms | |
| Peake et al. | Selected contribution: regulatory pathways involved in mechanical induction of c-fos gene expression in bone cells | |
| Fujii et al. | High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. | |
| Tufvesson et al. | Biglycan and decorin induce morphological and cytoskeletal changes involving signalling by the small GTPases RhoA and Rac1 resulting in lung fibroblast migration | |
| Schmid et al. | Differential expression of TGF β 1, β 2 and β 3 genes during mouse embryogenesis | |
| Sasaki et al. | Expression of fibulin-2 by fibroblasts and deposition with fibronectin into a fibrillar matrix | |
| Pasqualini et al. | A study of the structure, function and distribution of β5 integrins using novel anti-β5 monoclonal antibodies | |
| Knudsen et al. | Trigramin, an RGD-containing peptide from snake venom, inhibits cell-substratum adhesion of human melanoma cells | |
| Oono et al. | Expression of type VI collagen mRNA during wound healing | |
| Forsprecher et al. | Transglutaminase-mediated oligomerization promotes osteoblast adhesive properties of osteopontin and bone sialoprotein | |
| Söder et al. | Production and secretion of an interleukin‐l‐like factor is stage‐dependent and correlates with spermatogonial DNA synthesis in the rat seminiferous epithelium | |
| Ylänne et al. | Platelet glycoprotein IIb/IIIa complex in cultured cells. Localization in focal adhesion sites in spreading HEL cells | |
| Carson et al. | Emerging concepts in engineering extracellular matrix variants for directing cell phenotype | |
| Milam et al. | Il‐1β and prostaglandins regulate integrin mRNA expression | |
| Connor et al. | Independent expression of type I collagen and fibronectin by normal fibroblast-like cells | |
| Kürschner et al. | Construction, purification, and characterization of new interferon gamma (IFN gamma) inhibitor proteins. Three IFN gamma receptor-immunoglobulin hybrid molecules. | |
| DE68928183T2 (de) | Klasse i-mhc-modulation von oberflächenrezeptoraktivität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC4A | Lapse of provisional application due to refusal |